The transition, from open surgery to multi-port laparoscopic surgery, and then to single-port laparoscopic surgery and even natural orifice transluminal endoscopic surgery (NOTES), has reduced patient trauma significantly while increasing the complexity of surgical operations. It is a prevailing trend to use robotic technology to enhance the intuitiveness and precision of surgical procedures.
The SHURUI single-port surgical robot has been approved by the National Medical Products Administration of China, making it the first single-port surgical robot approved for use in both urology and gynecology surgery in China. The National Medical Products Administration (NMPA) commented highly on the SHURUI single-port robot: The surgical instruments of this product adopt internationally pioneering technologies with independent intellectual properties, which have technical advantages such as a wide range of motion, high payload capacity, and high reliability.
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.